According to the latest data from the Hong Kong Stock Exchange, GIC Private Limited increased its stake in CSTONE PHARMA-B (02616) by 904,500 shares on December 23, at a price of HK$5.8476 per share, with a total transaction value of approximately HK$5.2892 million. Following this acquisition, GIC's total shareholding has risen to approximately 119 million shares, representing a stake of 8.06%. Notably, as a top-tier international long-term capital investor, GIC's optimistic outlook on CSTONE PHARMA is clear and demonstrates a consistent pattern. Reviewing the trajectory of these acquisitions, since GIC first disclosed a 5.49% stake in CSTONE PHARMA on August 18 this year, its buying activity has been continuous: following disclosures of further purchases on October 13 and November 10, its stake increased to 7.11%, culminating in the latest disclosed stake of 8.06%. Over a span of just over four months, from August 18 to the latest disclosure date of December 23, the stake has steadily grown, with cumulative purchases exceeding 38 million shares, which fully underscores the high level of recognition from this international sovereign wealth fund regarding the company's core value and long-term development potential.